Anti-LMP2 TCR-T cell therapy for the treatment of EBV-associated cancers
US12139523B2 · kind B2 · utility
0Cited by
0References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 26, 2019 |
| Grant date | Nov 12, 2024 |
| Priority date | — |
| Expiry date | Oct 8, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides compositions comprising anti-LMP2 TCR-T cell populations for the treatment of EBV-associated cancers and methods of making and using same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.